Deals and Financings   Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal; Shanghai Ji Xing Pharma bought China commercialization rights to a Cytokinetics heart failure treatment in a $400 million pact; Shanghai Nuance Pharma acquired  China  rights to AeroFact™, an inhaled RDS therapy developed by  Ireland 's Aerogen, in a $213 million deal; ArriVent Biopharma of Philadelphia formed a $100 million collaboration with San Francisco 's Aarvik to develop a novel cancer therapeutic for global markets;   Changchun GeneScience signed a $43 million deal with Luye Pharma to commercialize two transdermal patch products in China for Alzheimer's; TandemAI, a Suzhou AI-based drug discovery company, raised $25 million in pre-A financings for its AI-wet lab drug discovery operations;  Company News   BeiGene launched the BeiGene Bioisland Innovation Center in  Guangzhou to enable young drug/device companies to develop novel cutting-edge medical innovations;  Trials and Approvals   Suzhou CStone Pharma reported its anti-PD-L1 monoclonal antibody was approved in China for first-line use in non-small cell lung cancer; Shanghai Zai Lab said its partner argenx SE was approved for a  US  launch of its myasthenia gravis therapy;  Covid-19 Pandemic   Shanghai Everest Medicines reported its mRNA Omicron-tailored COVID-17 vaccine will be tested as part of a WHO clinical trial.  Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235) (NYSE: NVS) (NSDQ: CYTK) (HK: 2616) (NSDQ: ZLAB; HK: 9688) (Euronext/NSDQ: ARGX) (HK:1952) Share this with colleagues: // //